
THE GENERAL ASSEMBLY OF PENNSYLVANIA

SENATE BILL

No. 920 Session of
2019

INTRODUCED BY PHILLIPS-HILL, COLLETT, MARTIN, YUDICHAK, BAKER,
MENSCH, STEFANO, J. WARD AND LEACH, DECEMBER 16, 2019

REFERRED TO BANKING AND INSURANCE, DECEMBER 16, 2019

AN ACT

1 Amending the act of May 17, 1921 (P.L.682, No.284), entitled "An
2 act relating to insurance; amending, revising, and
3 consolidating the law providing for the incorporation of
4 insurance companies, and the regulation, supervision, and
5 protection of home and foreign insurance companies, Lloyds
6 associations, reciprocal and inter-insurance exchanges, and
7 fire insurance rating bureaus, and the regulation and
8 supervision of insurance carried by such companies,
9 associations, and exchanges, including insurance carried by
10 the State Workmen's Insurance Fund; providing penalties; and
11 repealing existing laws," in quality health care
12 accountability and protection, further providing for
13 definitions and for responsibilities of managed care plans;
14 providing for preauthorization standards and for
15 preauthorization costs; further providing for continuity of
16 care; providing for step therapy protocols; further providing
17 for information for enrollees, for required disclosure and
18 for operational standards; providing for preauthorization and
19 adverse determinations, for appeals, for access requirements
20 in service areas, for uniform preauthorization form, for
21 preauthorization exemptions and for data collection and
22 reporting.

23 The General Assembly of the Commonwealth of Pennsylvania
24 hereby enacts as follows:

25 Section 1. The definitions of "emergency service," "health
26 care service," "prospective utilization review," "utilization
27 review" and "utilization review entity" in section 2102 of the
28 act of May 17, 1921 (P.L.682, No.284), known as The Insurance

1 Company Law of 1921, are amended and the section is amended by
2 adding definitions to read:

3 Section 2102. Definitions.--As used in this article, the
4 following words and phrases shall have the meanings given to
5 them in this section:

6 * * *

7 "Administrative defect." A deficiency, error, mistake or
8 missing information that serves as the basis of an adverse
9 determination issued by a utilization review entity as
10 justification to deny preauthorization.

11 "Adverse determination." The following apply:

12 (1) The term means a decision made by a utilization review
13 entity from a preauthorization request that:

14 (i) the health care services furnished or proposed to be
15 furnished to an insured:

16 (A) are not medically necessary;

17 (B) are experimental or investigational; or

18 (C) result from an administrative denial; or

19 (ii) denies, reduces or terminates benefit coverage.

20 (2) The term includes a decision to deny a step therapy
21 exception request under section 2118.

22 (3) The term does not include a decision to deny, reduce or
23 terminate services which are not covered for reasons other than
24 their medical necessity or experimental or investigational
25 nature.

26 * * *

27 "Appeal." A formal request, either verbal or in writing, to
28 reconsider a determination to not authorize a health care
29 service prior to the service being provided. The term does not
30 apply to grievances filed under section 2161.

1 "Appeal procedure." A formal process that permits an insured
2 or an attending physician or a designee, health care
3 practitioner or facility on an insured's behalf, to appeal an
4 adverse determination rendered by a utilization review entity or
5 its designee utilization review entity or agent.

6 "Appropriate use criteria." Criteria that:

7 (1) define when and how often it is medically necessary and
8 appropriate to perform a specific test or procedure; and

9 (2) are derived from documents of professional societies
10 that are evidence-based or, when evidence is conflicting or
11 lacking, from expert consensus panels and which documents
12 include published clinical guidelines for appropriate use for
13 the specific clinical scenario under consideration.

14 "Authorization." A determination by a utilization review
15 entity that:

16 (1) a health care service has been reviewed and, based on
17 the information provided, satisfies the utilization review
18 entity's requirements for medical necessity;

19 (2) the health care service reviewed is a covered service;
20 and

21 (3) payment will be made for the health care service.

22 * * *

23 "Clinical criteria." Policies, screening procedures,
24 determination rules, determination abstracts, clinical
25 protocols, practice guidelines and medical protocols set forth
26 in a written document available for peer-to-peer review by a
27 peer within the same profession and specialty and subject to
28 challenge by an insured when used as a basis to withhold
29 preauthorization, deny coverage or otherwise modify coverage
30 which are used by a utilization review entity to determine the

1 medical necessity of health care services. Clinical criteria
2 shall:

3 (1) Be based on nationally recognized standards.

4 (2) Be developed in accordance with the current standards of
5 national accreditation entities.

6 (3) Reflect community standards of care.

7 (4) Ensure quality of care and access to needed health care
8 services.

9 (5) Be evidence-based or based on generally accepted expert
10 consensus standards.

11 (6) Be sufficiently flexible to allow deviations from norms
12 when justified on a case-by-case basis.

13 (7) Be evaluated and updated if necessary at least annually.

14 "Clinical practice guidelines." A systematically developed
15 statement to assist in decision making by health care providers
16 and enrollees relating to appropriate healthcare for specific
17 clinical circumstances and conditions.

18 * * *

19 "Emergency service." Any health care service provided to an
20 enrollee, including prehospital transportation or treatment by
21 emergency medical services providers, after the sudden onset of
22 a medical condition that manifests itself by acute symptoms of
23 sufficient severity or severe pain such that a prudent layperson
24 who possesses an average knowledge of health and medicine could
25 reasonably expect the absence of immediate medical attention to
26 result in:

27 (1) placing the health of the enrollee or, with respect to a
28 pregnant woman, the health of the woman or her unborn child in
29 serious jeopardy;

30 (2) serious impairment to bodily functions; or

1 (3) serious dysfunction of any bodily organ or part.
2 Emergency transportation and related emergency service provided
3 by a licensed ambulance service shall constitute an emergency
4 service.

5 * * *

6 "Expedited appeal." A formal request, either verbal or in
7 writing, to reconsider an adverse determination to not authorize
8 emergency health care services or urgent health care services.

9 "Final adverse determination." An adverse determination that
10 has been upheld by a utilization review entity at the completion
11 of the utilization review entity's internal appeals process.

12 * * *

13 "Health care service." Any [covered] treatment, admission,
14 procedure, test used to aid in diagnosis or the provision of the
15 applicable treatment, pharmaceutical products, medical supplies
16 and equipment or other services, including behavioral health[,
17 prescribed or otherwise] provided or proposed to be provided by
18 a health care provider to an enrollee under a managed care plan
19 contract.

20 "Insured." A policyholder, subscriber, covered person or
21 other individual who is entitled to receive health care services
22 or benefits from a health insurer under a health plan or other
23 health insurance coverage under a managed care plan. Where
24 applicable, the term includes an individual's legally authorized
25 representative.

26 * * *

27 "Medically necessary health care services." Health care
28 services that a prudent health care provider would provide to a
29 patient for the purpose of preventing, diagnosing or treating an
30 illness, injury or disease or its symptoms in a manner that is:

1 (1) in accordance with generally accepted standards of
2 medical practice based on clinical criteria;
3 (2) appropriate in terms of type, frequency, extent, site
4 and duration pursuant to clinical criteria; and
5 (3) not primarily for the economic benefit of the health
6 plans and purchasers or for the convenience of the patient,
7 treating physician or other health care provider.

8 "Medication assisted treatment" or "MAT." The use of Food
9 and Drug Administration-approved medications, including
10 methadone, buprenorphine, alone or in combination with naloxone,
11 or naltrexone, in combination with counseling and behavioral
12 therapies, to provide a comprehensive approach to the treatment
13 of substance use disorders.

14 "NCPDP SCRIPT standard." The National Council for
15 Prescription Drug Programs SCRIPT Standard Version 201310, the
16 most recent standard adopted by the Department of Health and
17 Human Services or a subsequently related version, provided that
18 the new version is backwards-compatible to the current version
19 adopted by the Department of Health and Human Services. The
20 NCPDP SCRIPT standard applies to the provision of pharmaceutical
21 or pharmacological products.

22 "Nonurgent health care service." A health care service
23 provided to an enrollee that is not considered an emergency
24 service or an urgent health care service.

25 * * *

26 "Preauthorization." The process by which a utilization
27 review entity determines the medical necessity of otherwise
28 covered health care services prior to authorizing coverage and
29 the rendering of the health care services, including, but not
30 limited to, preadmission review, pretreatment review,

1 utilization management and case management. The term includes a
2 health insurer's or utilization review entity's requirement that
3 an insured or health care practitioner notify the health insurer
4 or utilization review agent prior to providing a health care
5 service.

6 * * *

7 ["Prospective utilization review." A review by a utilization
8 review entity of all reasonably necessary supporting information
9 that occurs prior to the delivery or provision of a health care
10 service and results in a decision to approve or deny payment for
11 the health care service.]

12 * * *

13 "Step therapy exception." A step therapy protocol that is
14 overridden in favor of immediate coverage of the health care
15 provider's selected prescription drug.

16 "Step therapy protocol." A protocol, policy or program that
17 establishes the specific sequence in which medically appropriate
18 prescription drugs for a specified medical condition are used by
19 a particular patient and are covered by a managed care plan.

20 "Urgent health care service." The following apply:

21 (1) A health care service deemed by a provider to require
22 expedited preauthorization review in the event that any delay
23 may jeopardize the life or health of the insured or that a delay
24 in treatment could:

25 (i) negatively affect the ability of the insured to regain
26 maximum function; or

27 (ii) subject the insured to severe pain that cannot be
28 adequately managed without receiving the care or treatment that
29 is the subject of the utilization review as quickly as possible.

30 (2) The term does not include an emergency service or

1 nonurgent health care service.

2 "Utilization review." A system of prospective, concurrent or
3 retrospective utilization review performed by a utilization
4 review entity of the medical necessity and appropriateness of
5 health care services prescribed, provided or proposed to be
6 provided to an enrollee. The term includes preauthorization but
7 does not include any of the following:

8 (1) Requests for clarification of coverage, eligibility or
9 health care service verification.

10 (2) A health care provider's internal quality assurance or
11 utilization review process unless the review results in denial
12 of payment for a health care service.

13 "Utilization review entity." Any entity certified pursuant
14 to subdivision (h) that performs utilization review on behalf of
15 a managed care plan. The term includes:

16 (1) An employer with employees in this Commonwealth who are
17 covered under a health benefit plan or health insurance policy.

18 (2) An insurer that writes health insurance policies,
19 including preferred provider organizations as provided under
20 section 630.

21 (3) Pharmacy benefits managers responsible for managing
22 access of insureds to available pharmaceutical or
23 pharmacological care.

24 (4) Any other individual or entity that provides, offers to
25 provide or administers hospital, outpatient, medical or other
26 health benefits to an individual treated by a health care
27 provider in this Commonwealth under a policy, plan or contract.

28 (5) A health insurer if the health insurer performs
29 utilization review.

30 Section 2. Section 2111 of the act is amended by adding

1 paragraphs to read:

2 Section 2111. Responsibilities of Managed Care Plans.--A
3 managed care plan shall do all of the following:

4 * * *

5 (14) Make updates to its enrollment eligibility information
6 within thirty (30) days of receiving updated enrollment
7 information. Updates in enrollment eligibility may occur due to
8 new enrollments, coordination of benefits or termination of
9 benefits. If a managed care plan fails to update eligibility
10 information in a timely manner, the managed care plan may not
11 deny payment due to enrollment information being inaccurate for
12 a date of service if current eligibility information was
13 available. In the event of a retroactive termination or a
14 determination that an enrollee was ineligible for benefits, a
15 health plan may recover any payments made in error within thirty
16 (30) days of the date of service.

17 (15) Establish rules pertaining to the timely filing of
18 health care provider claims that require a health care
19 provider's filing duty to commence based on the following,
20 whichever occurs last:

21 (i) when the patient is discharged;

22 (ii) when the patient presents complete and accurate
23 insurance information; or

24 (iii) when authorization or approval is confirmed by the
25 managed care plan.

26 Section 3. The act is amended by adding sections to read:

27 Section 2114. Preauthorization Standards.--(a) No later
28 than one hundred eighty (180) days after the effective date of
29 this section, preauthorization requests shall be accessible to
30 health care providers and accepted by insurers and utilization

1 review organizations electronically through a secure electronic
2 transmission platform. NCPDP SCRIPT standard shall be acceptable
3 for pharmaceutical or pharmacological care.

4 (b) Facsimiles, proprietary payer portals and electronic
5 forms shall not be considered electronic transmissions.

6 (c) Any restrictions that a utilization review entity places
7 on the preauthorization of health care services shall be:

8 (1) based on the medical necessity of those services and on
9 clinical criteria;

10 (2) applied consistently; and

11 (3) disclosed by the managed care plan or utilization review
12 entity under section 2136.

13 (d) Adverse determinations and final adverse determinations
14 made by a utilization review entity or agent of a utilization
15 review entity shall be based on clinical criteria.

16 (e) A utilization review entity may not deny coverage of a
17 health care service solely based on the grounds that the health
18 care service does not meet an evidence-based standard in the
19 event that:

20 (1) no independently developed, evidence-based standards can
21 be derived from documents published by professional societies;

22 (2) evidence-based standards are conflicting;

23 (3) evidence-based standards are lacking from expert
24 consensus panels; or

25 (4) existing standards for a particular health care item,
26 service, pharmaceutical product, test or imaging procedure are
27 not directly applicable to the health care service as being
28 applied.

29 (f) The following apply:

30 (1) Preauthorization shall not be required:

1 (i) when a medication, including noncontrolled generic
2 medication, or procedure prescribed for a patient is customary
3 and properly indicated or is a treatment for the clinical
4 indication as supported by peer-reviewed medical publications;

5 (ii) for a patient currently managed with an established
6 treatment regimen; or

7 (iii) for the provision of MAT for the treatment of an
8 opioid-use disorder.

9 (2) When a utilization review entity, through any agent,
10 contractor, employee or representative, informs a provider
11 seeking preauthorization for a medically necessary service that
12 preauthorization is not required, coverage for the service shall
13 be deemed approved.

14 (g) No later than one hundred eighty (180) days after the
15 effective date of this section, a payer shall accept and respond
16 to preauthorization requests under a pharmacy benefit through a
17 secure electronic transmission using the NCPDP SCRIPT standard.

18 Section 2115. Preauthorization Costs.--(a) In the event
19 that an insured is covered by more than one health plan that
20 requires preauthorization, the following provisions shall apply:

21 (1) Only the primary health plan may require that the
22 insured comply with the primary health plan's preauthorization
23 requirements.

24 (2) A secondary insurer or defined benefits plan may not
25 refuse payment for health care services solely on the basis that
26 the procedures set forth by the secondary insurer for
27 preauthorization were not followed. If the treatment is approved
28 by the primary insurer, the secondary insurer shall be bound by
29 the determination of medical necessity made by the primary
30 insurer.

1 (b) An appeal of an adverse determination or external review
2 of a final adverse determination shall be provided without
3 charge to the insured or insured's health care provider.

4 Section 4. Section 2117 of the act is amended by adding a
5 subsection to read:

6 Section 2117. Continuity of Care.--* * *

7 (g) The following apply:

8 (1) If the appeal of an adverse determination of a
9 preauthorization request concerns ongoing health care services
10 that are being provided pursuant to an initially authorized
11 admission or course of treatment, the health care services shall
12 continue to be paid for and provided without liability to the
13 insured or insured's health care provider until the later of the
14 following:

15 (i) thirty (30) days after the insured or insured's health
16 care provider receives notice of a final adverse determination
17 satisfying the requirements under section 2114(d) or the
18 determination of an external review entity if the decision on
19 adverse determination has been appealed through an external
20 review proceeding;

21 (ii) the duration of treatment; or

22 (iii) sixty (60) days.

23 (2) An insurer may not retroactively review the insurer's
24 decision to approve and provide health care services through
25 preauthorization, including preauthorizing for extending the
26 term or course of treatment. Notwithstanding any other provision
27 of law, the insurer may not retroactively recover the cost of
28 treatment either for the initial period of treatment or the
29 period of treatment provided to the insured as part of the
30 decision-making process to authorize coverage of additional

1 treatment periods.

2 Section 5. The act is amended by adding a section to read:

3 Section 2118. Step Therapy Protocols.--(a) Clinical
4 criteria used to establish a step therapy protocol shall be
5 based on clinical practice guidelines that:

6 (1) recommend that the prescription drugs be taken in the
7 specific sequence required by the step therapy protocol;

8 (2) are developed and endorsed by a multidisciplinary panel
9 of experts that manages conflicts of interest among the members
10 of the writing and review groups by:

11 (i) requiring members to disclose any potential conflicts of
12 interest with entities, including managed care plans and
13 pharmaceutical manufacturers, and recuse themselves from voting
14 if they have a conflict of interest;

15 (ii) using a methodologist to work with writing groups to
16 provide objectivity in data analysis and ranking of evidence
17 through the preparation of evidence tables and facilitating
18 consensus; and

19 (iii) offering opportunities for public review and comments;

20 (3) are based on research and medical practice published in
21 peer review medical journals;

22 (4) are created by an explicit and transparent process that:

23 (i) minimizes biases and conflicts of interest;

24 (ii) explains the relationship between treatment options and
25 outcomes;

26 (iii) rates the quality of evidence supporting
27 recommendations; and

28 (iv) considers relevant patient subgroups and preferences;

29 (5) are continually updated through a review of new
30 evidence, research and newly developed treatments;

1 (6) use peer-reviewed publications in the absence of
2 clinical guidelines that meet the requirements of this act; and
3 (7) consider the needs of atypical patient populations and
4 diagnoses when establishing clinical criteria.

5 (b) When a managed care plan or utilization review entity
6 restricts coverage of a prescription drug for the treatment of a
7 medical condition using a step therapy protocol, the enrollee
8 and health care provider shall have the right to request a step
9 therapy exception. A managed care plan or utilization review
10 entity may use its existing medical exceptions process to
11 satisfy this requirement. Information regarding the process
12 shall be made available on the managed care plan's or
13 utilization review entity's publicly accessible Internet
14 website.

15 (c) A step therapy exception shall be granted if any of the
16 following apply:

17 (1) The required prescription drug is contraindicated or
18 likely will cause an adverse reaction by, or physical or mental
19 harm to, the patient.

20 (2) The required prescription drug is expected to be
21 ineffective based on the known clinical characteristics of the
22 patient and the known characteristics of the prescription drug
23 regimen.

24 (3) The patient has tried the required prescription drug
25 while under the current or a previous managed care plan, or
26 another prescription drug in the same pharmacologic class or
27 with the same mechanism of action, and the prescription drug was
28 discontinued due to lack of efficacy or effectiveness,
29 diminished effect or an adverse event.

30 (4) The required prescription drug is not in the best

1 interests of the patient based on medical necessity.

2 (5) The patient is stable on a prescription drug selected by
3 the patient's health care provider for the medical condition
4 under consideration while on a current or previous managed care
5 plan.

6 (d) Decisions rendered pursuant to a step therapy request
7 shall be transmitted in writing to the enrollee and the
8 enrollee's health care provider.

9 (e) Upon the granting of a step therapy exception, the
10 managed care plan or utilization review entity shall authorize
11 coverage for the prescription drug prescribed by the patient's
12 treating health care provider.

13 (f) The managed care plan or utilization review entity shall
14 grant or deny a step therapy exception request within seventy-
15 two (72) hours of receipt. In situations where exigent
16 circumstances exist, the managed care plan or utilization review
17 entity shall grant or deny a step therapy request within twenty-
18 four (24) hours of receipt. An insured or an insured's health
19 care provider may appeal an adverse determination of a step
20 therapy exception request via telephone, facsimile, e-mail or
21 other expeditious method. The managed care plan or utilization
22 review entity shall grant or deny the appeal within the same
23 time frames as provided in this subsection. Failure of the
24 managed care plan or utilization review entity to comply with
25 the deadlines and other requirements specified in this
26 subsection shall result in the step therapy exception request
27 being deemed granted and paid by the managed care plan.

28 (g) Nothing in this section may be construed to:

29 (1) Require a managed care plan or other entity to establish
30 a new entity to develop clinical criteria used for step therapy

1 protocols.

2 (2) Prevent a managed care plan or utilization review entity
3 from requiring a pharmacist to effect substitutions of
4 prescription drugs consistent with State law.

5 (3) Prevent a health care provider from prescribing a
6 prescription drug that is determined to be medically necessary.

7 Section 6. The heading of Subarticle (f) of Article XXI of
8 the act is amended to read:

9 (f) Information for Enrollees and Health Care Providers.

10 Section 7. Section 2136 of the act is amended by adding a
11 subsection to read:

12 Section 2136. Required Disclosure.--* * *

13 (c) If a utilization review entity intends to implement a
14 new preauthorization requirement or restriction or amend an
15 existing requirement or restriction, the utilization review
16 entity shall provide contracted health care providers and
17 insureds with written notice of the new or amended requirement
18 or amendment not less than sixty (60) days before the
19 requirement or restriction is implemented. The notice shall be
20 in writing and if served upon health care providers, be provided
21 by certified mail, return receipt requested. The requirement of
22 certified mail return receipt requested can be satisfied if the
23 utilization review entity provides notice to a specified
24 individual named in the contract with the health care provider
25 for service of notices, under which circumstances the specified
26 person may receive notice by e-mail, return receipt requested.

27 Section 8. Section 2152(a)(4) and (6) are amended, the
28 subsection is amended by adding paragraphs and the section is
29 amended by adding subsections to read:

30 Section 2152. Operational Standards.--(a) A utilization

1 review entity shall do all of the following:

2 * * *

3 (4) Conduct utilization reviews based on the medical
4 necessity and appropriateness of the health care service being
5 reviewed and provide notification within the following time
6 frames:

7 (i) A prospective utilization review decision shall be
8 communicated within two (2) business days of the receipt of all
9 supporting information reasonably necessary to complete the
10 review.

11 (ii) A concurrent utilization review decision shall be
12 communicated within one (1) business day of the receipt of all
13 supporting information reasonably necessary to complete the
14 review.

15 (iii) A retrospective utilization review decision shall be
16 communicated within thirty (30) days of the receipt of all
17 supporting information reasonably necessary to complete the
18 review.

19 (iv) A utilization review entity shall allow an insured and
20 the insured's health care provider a minimum of one (1) business
21 day following an inpatient admission pursuant to an emergency
22 health care service or urgent health service to notify the
23 utilization review entity of the admission and any health care
24 services performed.

25 * * *

26 (6) Provide all decisions in writing to include the basis
27 and clinical rationale for the decision. For adverse
28 determinations of preauthorization decisions, a utilization
29 review entity shall provide all decisions to the insured and
30 insured's health care provider which shall also include

1 instructions concerning how an appeal may be filed. A
2 utilization review entity may not retroactively review the
3 medical necessity of any preauthorization which has been
4 previously approved or granted.

5 * * *

6 (9) Post to its publicly accessible Internet website:

7 (i) a current list of services and supplies requiring
8 preauthorization; and

9 (ii) written clinical criteria for preauthorization
10 decisions.

11 (10) Ensure that a preauthorization shall be valid for one
12 hundred eighty (180) days or the duration of treatment,
13 whichever is greater, from the date the health care provider
14 receives the preauthorization, so long as the insured is a
15 member of the plan.

16 (11) When performing preauthorization, only request copies
17 of medical records when a difficulty develops in determining the
18 medical necessity of a health care service. In that case, the
19 utilization review agent may only request the necessary and
20 relevant sections of the medical record.

21 (12) Not deny preauthorization nor delay preauthorization
22 for administrative defects. In the event an administrative
23 defect is discovered, a managed care plan shall allow a health
24 care provider the opportunity to remedy the administrative
25 defect within thirty (30) days of receiving notice.

26 * * *

27 (e) Failure by a utilization review entity to comply with
28 deadlines and other requirements specified for preauthorization
29 shall result in the health care service subject to review to
30 being deemed preauthorized and paid by the managed care plan.

1 (f) A utilization review entity shall approve claims for
2 health care services for which a preauthorization was required
3 and received from the managed care plan prior to the rendering
4 of the health care services, unless:

5 (1) the enrollee was not eligible for coverage at the time
6 the health care service was rendered. A managed care plan may
7 not deny payment for a claim on this basis if the enrollee's
8 coverage was retroactively terminated more than one hundred
9 twenty (120) days after the date of service, provided the claim
10 is submitted timely. If the claim is submitted after the timely
11 filing deadline, the managed care plan shall have no more than
12 thirty (30) days after the claim is received to deny the claim
13 on the basis the enrollee was not eligible for coverage on the
14 date of the health care service;

15 (2) the preauthorization was based on materially inaccurate
16 or incomplete information provided by the enrollee, their
17 designee or the health care provider, such that if the correct
18 or complete information had been provided, the preauthorization
19 would not have been granted; or

20 (3) there is a reasonable basis supported by material facts
21 available for review that the enrollee, the enrollee's designee
22 or the health care provider has engaged in fraud or abuse.

23 Section 9. The act is amended by adding sections to read:

24 Section 2161.1. Preauthorization and Adverse
25 Determinations.--(a) A utilization review entity shall ensure
26 that:

27 (1) Preauthorizations are made by a qualified licensed
28 health care provider who has knowledge of the items, services,
29 products, tests or procedures submitted for preauthorization.

30 (2) Adverse determinations are made by a physician. The

1 reviewing physician must possess a current and valid
2 nonrestricted license to practice medicine in this Commonwealth
3 and be board-certified in the specialty subject to the adverse
4 determination. A utilization review entity may seek approval
5 from the Insurance Commissioner to use a reviewing physician
6 that is not board-certified due to the unavailability of or
7 difficulty in finding a board-certified reviewing physician in a
8 given specialty. The Insurance Commissioner shall develop a form
9 and parameters for the request and shall transmit notice of the
10 request to the Legislative Reference Bureau for publication in
11 the Pennsylvania Bulletin. The Insurance Commissioner shall
12 provide at least ten (10) days for comment before rendering a
13 decision. The decision shall be transmitted to the Legislative
14 Reference Bureau for publication in the Pennsylvania Bulletin.

15 (b) Notice of a preauthorization shall be accompanied by a
16 unique preauthorization number and state all of the following:

- 17 (1) The specific health care services preauthorized.
18 (2) The next date for review.
19 (3) The total number of days approved.
20 (4) The date of admission or initiation of services, if
21 applicable.

22 (c) Neither the utilization review entity nor the payer or
23 health insurer that has retained the utilization review entity
24 may retroactively deny coverage for emergency or nonemergency
25 care that had been preauthorized when it was provided, if the
26 information provided was accurate.

27 (d) In the event a health care provider obtains
28 preauthorization for a service but the service provided is not
29 an exact match to the service that was preauthorized, but does
30 not materially depart from the service that was preauthorized, a

1 health plan shall not deny payment for the service only if:

2 (1) the date of service differs by less than thirty (30)
3 days;

4 (2) the physician or health care provider rendering the
5 service differs from the person indicated on the
6 preauthorization but is otherwise licensed and qualified to
7 provide the preauthorized service; or

8 (3) the service provided is different than what was
9 preauthorized but is commonly and appropriately a substitute
10 based on common procedural terminology.

11 (e) A health plan shall allow a health care provider to
12 resubmit a claim with corrected information for appropriate
13 reimbursement within thirty (30) days of receiving notice of an
14 adverse determination.

15 (f) The following apply:

16 (1) If a utilization review entity questions the medical
17 necessity of a health care service, the utilization review
18 entity shall notify the insured's health care provider that
19 medical necessity is being questioned and provide the basis of
20 the challenge in sufficient detail to allow the provider to
21 meaningfully address the concern of the utilization review
22 entity prior to issuing an adverse determination.

23 (2) The insured's health care provider or the health care
24 provider's designee and the insured or insured's designee shall
25 have the right to discuss the medical necessity of the health
26 care service with the utilization review physician.

27 (3) A utilization review entity questioning medical
28 necessity of a health care service which may result in an
29 adverse determination shall make the reviewing physician or a
30 physician who is part of a team making the decision available

1 telephonically between the hours of seven o'clock in the morning
2 (7 a.m.) and seven o'clock in the evening (7 p.m.).

3 (g) When making a determination based on medical necessity,
4 a utilization review entity shall base its determination on an
5 insured's presenting symptoms, diagnosis and information
6 available through the course of treatment, or at the time of
7 admission or presentation at the emergency department.

8 (h) A utilization review entity may not deny
9 preauthorization based solely on its determination that the
10 inpatient level of care is not appropriate. In the event a
11 utilization review entity determines an alternative level of
12 care is appropriate, it shall provide and cite the specific
13 criteria it has used as its basis for its level of care
14 determination to the health care provider. A health care
15 provider may appeal the determination.

16 (i) A utilization review entity may not issue an adverse
17 determination for a procedure due to lack of preauthorization if
18 the procedure is medically necessary or clinically appropriate
19 for the patient's medical condition and rendered at the same
20 time as a related procedure for which preauthorization was
21 required and received.

22 (j) When making a medical necessity determination, a
23 utilization review entity shall deem any hospital stay of at
24 least forty-eight (48) hours as meeting inpatient level of care
25 criteria.

26 (k) A utilization review entity shall make a
27 preauthorization or adverse determination and notify the insured
28 and the insured's health care practitioner as follows:

29 (1) For nonurgent health care services: within seventy-two
30 (72) hours of obtaining all of the necessary information to make

1 the preauthorization or adverse determination.

2 (2) For urgent health care services: within twenty-four (24)
3 hours of obtaining all of the necessary information to make the
4 preauthorization or adverse determination.

5 (1) No utilization review entity may require
6 preauthorization for an emergency service, including
7 postevaluation and poststabilization services.

8 Section 2161.2. Appeals.--(a) An expedited appeal shall be
9 provided as follows:

10 (1) An insured or the insured's health care provider may
11 request an expedited appeal of an adverse determination via
12 telephone, facsimile, e-mail or other expeditious method.

13 (2) Within one (1) day of receiving an expedited appeal and
14 all information necessary to decide the appeal, the utilization
15 review entity shall provide the insured and the insured's health
16 care provider written confirmation of the expedited review
17 determination.

18 (b) An appeal shall be reviewed only by a physician who is:

19 (1) Board-certified in the same specialty as a health care
20 practitioner who typically manages the medical condition or
21 disease.

22 (2) Currently in active practice in the same specialty as
23 the health care provider who typically manages the medical
24 condition or disease.

25 (3) Knowledgeable of, and has experience in, providing the
26 health care services under appeal.

27 (4) Under contract with a utilization review entity to
28 perform reviews of appeals, and payment of fees due to the
29 physician under the contract may not be made subject to or
30 contingent upon the outcome of the appeal. The physician may

1 also be subject to a provider agreement with the insurer as a
2 provider but may not receive any other fees or compensation from
3 the insurer. The physician's receipt of compensation from the
4 utilization review entity may not be considered by the physician
5 in determining the outcome of the appeal. The physician shall
6 render independent and accurate medical judgment in reaching the
7 physician's opinion or conclusion. Failure to comply with this
8 provision shall render the physician subject to licensure
9 disciplinary action by the appropriate State licensing board.

10 (5) Not involved in making the adverse determination.

11 (6) Familiar with all known clinical aspects of the health
12 care services under review, including, but not limited to, all
13 pertinent medical records provided to the utilization review
14 entity by the insured's health care provider and any relevant
15 records provided to the utilization review entity by a health
16 care facility.

17 (c) The utilization review entity shall ensure that appeal
18 procedures satisfy the following requirements:

19 (1) The insured and the insured's health care provider may
20 challenge the adverse determination and have the right to appear
21 in person before the physician who reviews the adverse
22 determination.

23 (2) The utilization review entity shall provide the insured
24 and the insured's health care provider with written notice of
25 the time and place concerning where the review meeting will take
26 place. Notice shall be given to the insured's health care
27 provider at least fifteen (15) days in advance of the review
28 meeting.

29 (3) If the insured or the insured's health care provider
30 appear in person, the utilization review entity shall offer the

1 insured or insured's health care provider the opportunity to
2 communicate with the reviewing physician, at the utilization
3 review entity's expense, by conference call, video conferencing
4 or other available technology.

5 (4) The physician performing the review of the appeal shall
6 consider all information, documentation or other material
7 submitted in connection with the appeal without regard to
8 whether the information was considered in making the adverse
9 determination.

10 (d) The following deadlines apply:

11 (1) A utilization review entity shall decide an expedited
12 appeal and notify the insured and health care provider of the
13 determination within one (1) day after receiving a notice of
14 expedited appeal by the insured or the insured's health care
15 provider and all information necessary to decide the appeal.

16 (2) A utilization review entity shall issue a written
17 determination concerning a nonexpedited appeal not later than
18 ten (10) days after receiving a notice of appeal from an insured
19 or insured's health care provider and all information necessary
20 to decide the appeal.

21 (e) Written notice of final adverse determinations shall be
22 provided to the insured and the insured's health care provider.

23 (f) If the insured or the insured's health care provider, or
24 a designee on behalf of either the insured or the insured's
25 health care provider, has satisfied the necessary requirements
26 for the appeal of an adverse determination through the
27 preauthorization process and the appeal has resulted in a
28 continued adverse determination either based in lack of medical
29 necessity or an administrative defect, the insured, the
30 insured's health care provider or a designee on behalf of either

1 of them is authorized to file a consumer complaint with the
2 Insurance Department. The complaint shall be adjudicated without
3 unnecessary delay and a determination issued by the Insurance
4 Department with appropriate sanctions if applicable pursuant to
5 the authority given to the Insurance Department. The following
6 apply:

7 (1) If an insured, the insured's provider or a designee on
8 behalf of the insured or the insured's provider files a consumer
9 complaint with the Department of Health or the Office of the
10 Attorney General pursuant to their authority to receive
11 complaints, a copy of the complaint filed with either of those
12 agencies shall be forwarded to the Insurance Department and the
13 copy shall serve as a new consumer complaint which shall be
14 adjudicated pursuant to this section and all other applicable
15 law.

16 (2) Nothing in this section is intended to preclude an
17 insured or an insured's designee from filing a separate consumer
18 complaint with the Insurance Department for failure to comply
19 with the requirements of this act as it applies to
20 preauthorization processes or denial of health insurance
21 coverage generally.

22 Section 2195. Access Requirements in Service Areas.--If a
23 patient's safe discharge is delayed for any reason, including
24 lack of available posthospitalization services, including, but
25 not limited to, skilled nursing facilities, home health services
26 and postacute rehabilitation, the managed care plan shall
27 reimburse the hospital for each subsequent date of service at
28 the greater of the hospital's contracted rate with the managed
29 care plan for the current level of care and service or the full
30 diagnostic related group payment divided by the mean length of

1 stay for that particular diagnostic related group.

2 Section 2196. Uniform Preauthorization Form.--(a) Within
3 three (3) months of the effective date of this section, the
4 Insurance Department shall convene a panel to develop a uniform
5 preauthorization form that health care providers in this
6 Commonwealth shall use to request preauthorization and that
7 health insurers shall accept as sufficient to request
8 preauthorization of health care services.

9 (b) The panel shall consist of not fewer than ten (10)
10 persons. Equal representation shall be afforded to the
11 physician, health care facility, employer, health insurer and
12 consumer protection communities within this Commonwealth.

13 (c) Within one (1) year of the effective date of this
14 section, the panel shall conclude development of the uniform
15 preauthorization form and the Insurance Department shall make
16 the uniform preauthorization form available to health care
17 providers in this Commonwealth and utilization review entities
18 and agents.

19 Section 2197. Preauthorization Exemptions.--(a) When
20 appropriate use criteria exist for a particular health care
21 service, the health care service shall be exempt from
22 preauthorization if the provision of the health care service
23 comports with applicable appropriate use criteria.

24 (b) A health care service that has been provided following
25 approval through the preauthorization procedures provided by the
26 insurer or which is not subject to preauthorization procedures
27 may not be subject to retrospective review based on medical
28 necessity related to the preauthorization.

29 Section 2198. Data Collection and Reporting.--The Insurance
30 Department shall maintain and collect data on the number of

1 appeals filed by enrollees, enrollee designees and health care
2 providers with utilization review entities. The Insurance
3 Department shall, on an annual basis, publish a report made
4 accessible on its publicly accessible Internet website and serve
5 a copy of the report on the Banking and Insurance Committee of
6 the Senate and the Insurance Committee of the House of
7 Representatives that identifies the following data by place and
8 type of service:

9 (1) The total number of appeals filed against utilization
10 review entities.

11 (2) The number and percentage of appeals filed against each
12 utilization review entity.

13 (3) The total number of appeals found in favor of
14 utilization review entities.

15 (4) The number and percentage of appeals found in favor of
16 each managed care plan.

17 (5) The total number of appeals found in favor of the
18 enrollee, designee or health care provider.

19 (6) The number and percentage of appeals found in favor of
20 the enrollee, designee or health care provider against each
21 managed care plan.

22 (7) The Insurance Department shall evaluate, monitor and
23 track health plan statistics in accordance with the information
24 gathered under this section and investigate negative trends and
25 outliers. In addition, the Insurance Department shall facilitate
26 meetings between health care providers and managed care plans to
27 discuss and resolve disputes.

28 Section 10. This act shall take effect in 60 days.